EPHA5

Across TCGA pan-cancer cohorts, EPHA5 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated EPHA5 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher EPHA5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EPHA5 expression acts as an unfavorable survival marker.

GBM and HNSC are the cancer types where EPHA5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.218	0.519	<.001	22	view →
HNSC	OS	Median	III,IV	0.577	0.861	.033	5	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

EPHA5–GBM (DFS)

Open the GBM breakdown →